Literature DB >> 10050276

DNA vaccines: technology and application as anti-parasite and anti-microbial agents.

J B Alarcon1, G W Waine, D P McManus.   

Abstract

DNA vaccines have been termed The Third Generation of Vaccines. The recent successful immunization of experimental animals against a range of infectious agents and several tumour models of disease with plasmid DNA testifies to the powerful nature of this revolutionary approach in vaccinology. Among numerous advantages, a major attraction of DNA vaccines over conventional vaccines is that they are able to induce protective cytotoxic T-cell responses as well as helper T-cell and humoral immunity. Here we review the current state of nucleic acid vaccines and cover a wide range of topics including delivery mechanisms, uptake and expression of plasmid DNA, and the types of immune responses generated. Further, we discuss safety issues, and document the use of nucleic acid vaccines against viral, bacterial and parasitic diseases, and cancer. The early potential promise of DNA vaccination has been fully substantiated with recent, exciting developments including the movement from testing DNA vaccines in laboratory models to non-human primates and initial human clinical trials. These advances and the emerging voluminous literature on DNA vaccines highlight the rapid progress that has been made in the DNA immunization field. It will be of considerable interest to see whether the progress and optimism currently prevailing can be maintained, and whether the approach can indeed fulfil the medical and commerical promise anticipated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050276     DOI: 10.1016/s0065-308x(08)60152-9

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  28 in total

Review 1.  DNA vaccines: roles against diseases.

Authors:  Kishwar Hayat Khan
Journal:  Germs       Date:  2013-03-01

2.  Multi-epitope recombinant vaccine induces immunoprotection against mixed infection of Eimeria spp.

Authors:  Jun Ding; Weifeng Qian; Qun Liu; Qiaorong Liu
Journal:  Parasitol Res       Date:  2011-12-27       Impact factor: 2.289

3.  Construction of an expression plasmid (vector) encoding Brucella melitensis outer membrane protein, a candidate for DNA vaccine.

Authors:  Fatemeh Vahedi; Elnaz Ghorbani; Tahereh Falsafi
Journal:  Rep Biochem Mol Biol       Date:  2013-04

Review 4.  Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.

Authors:  A G Ross; A C Sleigh; Y Li; G M Davis; G M Williams; Z Jiang; Z Feng; D P McManus
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 5.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 6.  Daedalic DNA vaccination against self antigens as a treatment for chronic kidney disease.

Authors:  Yuan Min Wang; Jimmy Jianheng Zhou; Ya Wang; Debbie Watson; Geoff Yu Zhang; Min Hu; Huiling Wu; Guoping Zheng; Yiping Wang; Anne M Durkan; David C H Harris; Stephen I Alexander
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

7.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

8.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

9.  The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.

Authors:  Alaa Bassuny Ismael; Dalila Sekkai; Christine Collin; Daniel Bout; Marie-Noëlle Mévélec
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.